Transcriptome sequencing of malignant pleural mesothelioma tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 9, 2008, Pages 3521-3526

  Sugarbaker, David J ^a   Richards, William G ^a   Gordon, Gavin J ^a   Dong, Lingsheng ^a   De Rienzo, Assunta ^a   Maulik, Gautam ^a   Glickman, Jonathan N ^a   Chirieac, Lucian R ^a   Hartman, Mor Li ^a   Taillon, Bruce E ^b   Du, Lei ^b   Bouffard, Pascal ^b   Kingsmore, Stephen F ^c   Miller, Neil A ^c   Farmer, Andrew D ^c   Jensen, Roderick V ^d   Gullans, Steven R ^e   Bueno, Raphael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b 454 Life Sciences Corporation   (United States)

^c NATIONAL CENTER FOR GENOME RESOURCES   (United States)

^d VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^e RxGen Inc   (United States)

Author keywords

Bioinformatics; DNA sequencing; Loss of heterozygosity; Lung cancer; Tumor mutations

Indexed keywords

TRANSCRIPTOME; ACTIVIN RECEPTOR 1; ACVR1 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; AVEN PROTEIN, HUMAN; CELL NUCLEUS ANTIGEN; DNA BINDING PROTEIN; KU ANTIGEN; MEMBRANE PROTEIN; PDZK1IP1 PROTEIN, HUMAN; RNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EPIGENETICS; GENE DELETION; HUMAN; NUCLEOTIDE SEQUENCE; PLEURA MESOTHELIOMA; POINT MUTATION; PRIORITY JOURNAL; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSCRIPTOMICS; ZYGOSITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MESOTHELIOMA; MUTATION; PLEURA TUMOR; RNA EDITING;

ACTIVIN RECEPTORS, TYPE I; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, NUCLEAR; APOPTOSIS REGULATORY PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MEMBRANE PROTEINS; MESOTHELIOMA; MUTATION; NEOPLASM PROTEINS; PLEURAL NEOPLASMS; POINT MUTATION; RNA EDITING; RNA, NEOPLASM; SEQUENCE DELETION;

EID: 42149162212     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712399105     Document Type: Article

References (45)

1. Sjoblom T, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
2. Futreal PA, Wooster R, Stratton MR (2006) Somatic mutations in human cancer: Insights from resequencing the protein kinase gene family. Cold Spring Harbor Symp Quant Biol 70:43-49.
3. Greenman C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
4. Balsara BR, et al. (1999) Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 59:450-454.
5. Lee M, et al. (2007) Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 3:832-838.
6. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692.
7. Haber DA, Settleman J (2007) Cancer: Drivers and passengers. Nature 446:145-456.
8. Britton M (2002) The epidemiology of mesothelioma. Semin Surg Oncol 29:18-25.
9. Whitson BA, Kratzke RA (2006) Molecular pathways in malignant pleural mesothelioma. Cancer Lett 239:183-189.
10. Baldassarre M, et al. (2003) Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol Biol Cell 14:1074-1084.
11. De Rienzo A, Jhanwar SC, Testa JR (2000) Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 28:337-341.
12. Huncharek M (1995) Genetic factors in the aetiology of malignant mesothelioma. Eur J Cancer 31A:1741-1747.
13. Musti M, et al. (2006) Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 170:9-15.
14. Pylkkanen L, et al. (2002) Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 9:955-959.
15. Yang H, et al. (2006) TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103:10397-10402.
16. Gordon GJ, et al. (2002) Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23:1017-1024.
17. Gordon GJ, et al. (2007) Inhibitor of apoptosis proteins are regulated by tumor necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211:439-446.
18. Margulies M, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380.
19. Green RE, et al. (2006) Analysis of one million base pairs of Neanderthal DNA. Nature 444:330-336.
20. Richards WG, et al. (2007) Microaliquoting: A technique for precision histologic annotation and cell content optimization of frozen tissue specimens. Biotech Histochem 1-9.
21. Jongeneel CV, et al. (2005) An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res 15:1007-1014.
22. Gordon GJ, et al. (2002) Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62:4963-4967.
23. Gordon GJ, et al. (2005) Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166:1827-1840.
24. Benz CC, et al. (2006) Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. Genes Chromosomes Cancer 45:983-994.
25. Redon R, et al. (2006) Global variation in copy number in the human genome. Nature 444:444-454.
26. Weir BA, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-898.
27. Walker JR, Corpina RA, Goldberg J (2001) Structure of the Ku heterodimer bound to DNA, its implications for double-strand break repair. Nature 412:607-614.
28. Kaminker JS, et al. (2007) Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 67:465-473.
29. Galigniana MD, Harrell JM, O'Hagen HM, Ljungman M, Pratt WB (2004) Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem 279:22483-22489.
30. Kocher O, Cheresh P, Brown LF, Lee SW (1995) Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res 1:1209-1215.
31. Kocher O, Cheresh P, Lee SW (1996) Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol 149:493-500.
32. Kocher O, et al. (1999) PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab Invest 79:1161-1170.
33. Fischer H, Stenling R, Rubio C, Lindblom A (2001) Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis 22:875-878.
34. Luparello C, Sirchia R (2005) Type V collagen regulates the expression of apoptotic and stress response genes by breast cancer cells. J Cell Physiol 202:411-421.
35. Kulawiec M, et al. (2006) Proteomic analysis of mitochondria-to-nucleus retrograde response in human cancer. Cancer Biol Ther 5:967-975.
36. Hoffman L, Gorbea C, Rechsteiner M (1999) Identification, molecular cloning, and characterization of subunit 11 of the human 26S proteasome. FEBS Lett 449:88-92.
37. Adams J (2004) The proteosome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360.
38. Zou TT, et al. (2002) Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21:4855-4862.
39. Chau BN, Cheng EH, Kerr DA, Hardwick JM (2000) Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 6:31-40.
40. Gordon GJ (2007) Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 211:447-454.
41. Paydas S, et al. (2003) Survivin and aven: Two distinct antiapoptotic signals in acute leukemias. Ann Oncol 14:2045-2050.
42. Kristiansen M, et al. (2005) High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J Med Genet 42:877-880.
43. Li G, et al. (2006) Skewed X chromosome inactivation of blood cells is associated with early development of lung cancer in females. Oncol Rep 16:859-864.
44. Scholzova E, Malik R, Sevcik J, Kleibl Z (2007) RNA regulation and cancer development. Cancer Lett 246:12-23.
45. Eisenberg E, et al. (2005) Identification of RNA editing sites in the SNP database. Nucleic Acids Res 33:4612-4617.